Table 1:
Baseline clinicopathological data of included patients
| Variables | All patients (n = 565) |
Propensity-matched (n = 261) |
||||
|---|---|---|---|---|---|---|
| PM (n = 66) | No-PM (n = 499) | SMD | PM (n = 59) | No-PM (n = 202) | SMD | |
| Age (years), median (IQR) | 45.0 (16–62) | 52.0 (18–63) | 0.571 | 45.0 (16–62) | 45 (20.8–63) | 0.114 |
| Sex, n (%) | 0.132 | 0.021 | ||||
| Male | 44 (66.7) | 301 (60.3) | 40 (67.8) | 135 (66.8) | ||
| Female | 22 (33.3) | 198 (39.7) | 19 (32.2) | 67 (33.2) | ||
| Race, n (%) | 0.112 | 0.114 | ||||
| White | 53 (80.3) | 389 (78.0) | 48 (81.4) | 155 (76.7) | ||
| Black | 9 (13.6) | 65 (13.0) | 7 (11.9) | 30 (14.9) | ||
| Other | 4 (6.1) | 45 (9.0) | 4 (6.4) | 17 (8.4) | ||
| Tissue, n (%) | 0.412 | 0.139 | ||||
| Bone | 32 (48.5) | 145 (29.1) | 27 (45.8) | 77 (38.1) | ||
| Soft tissue | 33 (50.0) | 346 (69.3) | 32 (54.2) | 121 (59.9) | ||
| Overlapping | 1 (1.5) | 8 (1.6) | 0 (0.0) | 4 (2.0) | ||
| Size (cm), median (IQR) | 10.8 (7.5–13.5) | 10.0 (7.7–15.0) | 0.233 | 11.0 (7.6–13.8) | 10.3 (7.0–150.0) | 0.011 |
| Grade, n (%) | 0.164 | 0.016 | ||||
| Low/intermediate | 11 (16.7) | 55 (11.0) | 10 (16.9) | 33 (16.3) | ||
| High | 55 (83.3) | 444 (89.0) | 49 (83.1) | 169 (83.7) | ||
| T stage,an (%) | 0.169 | 0.110 | ||||
| T1 | 13 (19.7) | 62 (12.4) | 12 (20.3) | 32 (15.8) | ||
| T2/T3 | 46 (69.7) | 339 (67.9) | 46 (78.0) | 163 (80.7) | ||
| Missing | 7 (10.6) | 98 (19.6) | 1 (1.7) | 7 (3.5) | ||
| N stage,an (%) | 0.389 | 0.080 | ||||
| N0 | 63 (95.5) | 378 (75.8) | 56 (94.9) | 195 (96.5) | ||
| N1 | 3 (4.5) | 73 (14.6) | 3 (5.1) | 7 (3.5) | ||
| Missing | 0 (0.0) | 48 (9.6) | 0 (0.0) | 0 (0.0) | ||
| Chemotherapy,bn (%) | 0.310 | 0.035 | ||||
| Yes | 50 (75.8) | 307 (61.5) | 45 (76.3) | 151 (74.8) | ||
| No/unknown | 16 (24.2) | 192 (38.5) | 14 (23.7) | 51 (25.2) | ||
| Radiation,bn (%) | 0.471 | 0.483 | ||||
| Yes | 23 (34.8) | 75 (15.0) | 23 (39.0) | 36 (17.8) | ||
| No | 43 (65.2) | 424 (85.0) | 36 (61.0) | 166 (82.2) | ||
a
AJCC 7th edition staging.
b
Adjuvant and/or neoadjuvant with respect to the primary disease.
IQR: interquartile range; PM: pulmonary metastasectomy; SMD: standardized mean difference.